Side-by-side comparison of AI visibility scores, market position, and capabilities
Gurugram India YC W20 digital therapeutics for diabetes/PCOD/thyroid/hypertension reversal serving 150M Indian chronic disease patients; $12.9M total (Accel/General Catalyst Series A 2021 + ₹50Cr pre-Series B 2023) competing with Twin Health.
Breathe Well-being is a Gurugram, India-based digital therapeutics platform — backed by Y Combinator (W20) with $12.9 million in total funding including a ₹50 crore ($6 million) pre-Series B in 2023 and a $5.5 million Series A in August 2021 led by Accel with General Catalyst, 3one4 Capital, and Scott Shleifer — providing Indians with clinically validated digital programs for reversing and managing Type 2 diabetes, PCOD (polycystic ovarian disease), thyroid disorders, and hypertension through structured weight loss programs combining personalized nutrition coaching, behavioral change support, and continuous glucose monitoring. Founded in 2020 with a mission to help 1 million Indians reverse Type 2 diabetes by 2025, Breathe targets India's 150 million chronic lifestyle disease patients.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.